Business
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation today announced that the Company’s Special Meeting of Stockholders, held on April 27, 2026, at 10:00 a.m. Eastern Time (“Special Meeting”) was adjourned, without any business being conducted, due to lack of the required qu
About this update from Hcw Biologics Inc.
[{"type":"image","alt":"HCW Biologics Inc.","displaySize":"","headline":null,"caption":"HCW Biologics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6KmwD3A_ctXK0d88uCG5hQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7","width":300,"height":150}},"lazy":false},{"type":"text","content":"MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation today announced that the Company’s Special Meeting of Stockholders, held on April 27, 2026, at 10:00 a.m. Eastern Time (“Special Meeting”) was adjourned, without any business being conducted, due to lack of the required quorum and the matters were adjourned to the Annual Meeting of Stockholders.","length":574,"tagName":"p"},{"type":"text","content":"The proposals presented to stockholders for their consideration at the Special Meeting will be included in the proposals presented to stockholders for their consideration for the Company’s Annual Meeting of Stockholders (“Annual Meeting”). The Annual Meeting is scheduled to take place virtually on June 15, 2026 at 10:00 a.m. Eastern Time.","length":340,"tagName":"p"},{"type":"text","content":"During the adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals set forth in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on April 28, 2026.","length":255,"tagName":"p"},{"type":"text","content":"The Company encourages all stockholders of record as of the record date of April 22, 2026 to vote in favor of these two proposals related warrants issued to Armistice Capital Master Fund Ltd. (“Armistice”). Armistice has invested $17.4 million in our Company to fuel our clinical development programs and provide corporate funds. The two proposals relate to warrants issued to Armistice to purchase up to 5,497,702 shares of Common Stock to be exercisable to purchase Common Stock at $0.6055 per share, subject to...